Clinical trial
Leveraging the Gut Microbiota in Pediatric Refractory Epilepsy: Safety and Feasibility of Oligofructose-enriched Inulin Supplementation for Dysbiosis and Seizure Control
NCT04705298 is registered in ClinicalTrials.gov with British Columbia Children's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Leveraging the Gut Microbiota in Pediatric Refractory Epilepsy: Safety and Feasibility of Oligofructose-enriched Inulin Supplementation for Dysbiosis and Seizure Control
- Lead sponsor
- British Columbia Children's Hospital
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- June 1, 2021
- Completion date
- September 1, 2022
- Enrollment
- 45 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.